Cagrilintide as a GLP-1 bridge or stack: what the REDEFINE data actually shows

The short version

• Cagrilintide is a copy of amylin, not a GLP-1 drug. Amylin is a fullness hormone your pancreas releases with insulin after meals; it works on a different part of the brain from GLP-1 medicines.
• REDEFINE 1 gave −20.4% at 68 weeks for CagriSema, versus −14.9% semaglutide alone, −11.5% cagrilintide alone and −3.0% placebo.
• That headline landed below the ~25% its maker had targeted - powerful, but in the same territory as tirzepatide rather than past it.
• REDEFINE 4, reported February 2026, missed non-inferiority against tirzepatide - 23.0% versus 25.5% at 84 weeks, establishing no superiority over the comparator, and it post-dates the 18 December 2025 NDA.
• Still investigational. As of 26 October 2026 CagriSema is filed, under FDA review and not approved, with no public decision date; Novo Nordisk expects a decision before the end of 2026.
• The "resensitizing bridge" idea was never tested. The trials studied the two medicines taken together, so whether a swap-in during a break does anything is unestablished, not disproven.

Updated October 2026: status re-checked 26 October 2026 (filed 18 December 2025, still under review, not approved, Q4 2026 guidance unchanged, no public PDUFA date, no advisory committee announced). Rewrote the summary in plain English, removed language that read as endorsing combined use, and replaced the supply-focused call to action with a bloodwork-first one.

Updated September 2026: status re-checked 24 September 2026: CagriSema remains under FDA review and unapproved, with still no publicly confirmed PDUFA date, which is itself the reportable status rather than a date to quote. Dates the REDEFINE 4 readout to February 2026 and states that it established no superiority over the comparator.

Updated September 2026: carries the Q4 2026 FDA decision milestone for CagriSema in place of the looser "late 2026" framing, and removes trial-arm dose figures from the tables and references in line with the no-dosing standard.

Updated August 2026: corrects the REDEFINE 4 head-to-head figures (23.0% vs 25.5% at 84 weeks) and notes that no PDUFA date has been publicly confirmed - the circulating "October 2026" date is an unofficial estimate.

---

Cagrilintide is the GLP-1 world's interesting outsider: it isn't a GLP-1 drug at all. It's a long-acting amylin analogue that suppresses appetite through a separate brain pathway, which is why it's studied alongside semaglutide rather than against it. In the pivotal REDEFINE 1 trial, the cagrilintide–semaglutide combination (CagriSema) produced about −20.4% body weight at 68 weeks - versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone - putting the combo in the top range of obesity treatments. The honest caveats up front: it's investigational, that headline number actually fell short of the ~25% its maker hoped for and doesn't decisively beat tirzepatide, and the popular idea of using cagrilintide as a "resensitizing bridge" during a drug holiday is not what the trials tested.

Here's the real picture.

Looking for the full picture? This page covers cagrilintide and the REDEFINE programme specifically. For how the whole class fits together - single, dual and triple agonists plus the amylin branch, with the 2026 trial data - start with GLP-1 generations compared. For the regulatory status of the combination itself, see CagriSema: where the FDA review stands.

2026 update - the head-to-head result. In REDEFINE 4, reported in February 2026, CagriSema (investigational) was compared directly with Zepbound (tirzepatide) and reached 23.0% weight loss versus 25.5% at 84 weeks, missing its primary endpoint of non-inferiority on weight loss and establishing no superiority over the comparator. Novo Nordisk's NDA (submitted 18 December 2025) rests primarily on the earlier REDEFINE 1 and REDEFINE 2 efficacy and safety data; REDEFINE 4 post-dates that package and was not the basis of the submission. No PDUFA date has been publicly confirmed by the FDA or Novo Nordisk, and that absence is the status of record rather than something this page is failing to report; company guidance points to a decision by late 2026, carried by Novo as a Q4 2026 regulatory milestone, and the frequently cited "October 2026" is an unofficial trade estimate, not a published PDUFA date. This doesn't make CagriSema a poor option - the amylin pathway is real and tolerability may suit some people - but it does undercut the assumption that a newer combination automatically beats an approved dual agonist. Full context: GLP-1 generations compared and CagriSema: where the FDA review stands.

See also: New to cagrilintide? Cagrilintide as a bridge or stack, in plain English explains the amylin pathway from scratch and answers whether cagrilintide lowers ghrelin. This page focuses on the REDEFINE trial numbers.

What cagrilintide actually is

Your pancreas co-secretes two hormones with every meal: insulin and amylin. Amylin signals fullness to the hindbrain (the area postrema and nearby nuclei), slows gastric emptying, and reduces food intake. Cagrilintide is a dual amylin and calcitonin receptor agonist (compound reference) engineered to last about a week - a synthetic, long-acting version of that natural satiety signal.

The key point: this is a different pathway from GLP-1 and GIP. Semaglutide (GLP-1) and tirzepatide (GLP-1 + GIP) work largely through incretin biology and the hypothalamus; amylin works through the brainstem. Two separate roads to the same destination - eating less - which is exactly why combining them is mechanistically appealing rather than redundant.

The REDEFINE 1 data, honestly

REDEFINE 1 was a large (3,417-adult), 68-week phase 3 trial that compared the combination against each component and placebo:

About 60% of CagriSema participants lost 20% or more, and 23% lost 30% or more - and 88% of those with prediabetes returned to normal blood sugar (Novo Nordisk; NEJM 2025). Those are genuinely strong numbers.

But two honest qualifiers matter. First, the combination of two appetite pathways clearly beat either drug alone - that's the real finding, and it validates the mechanism. Second, the 20.4% headline landed below the ~25% the manufacturer had publicly targeted, and it sits in broadly the same territory as tirzepatide's ~20–22.5% rather than leaping past it. CagriSema is a powerful tool, not the runaway winner some headlines implied. (REDEFINE 4's higher 23.0% figure comes from a different trial over a longer 84-week window; the two numbers are not interchangeable, and only the within-trial comparison against tirzepatide is meaningful.)

The "stack" rationale - the part that's real

The reason to combine, beyond the raw numbers, is complementary mechanisms at lower doses of each. Because amylin and GLP-1 hit different satiety circuits, pairing them can drive more total weight loss while potentially keeping each component's dose - and its gastrointestinal side effects - lower than maxing out a single drug. That's the legitimate, trial-supported logic behind co-administration, and it's why Novo Nordisk built CagriSema as a fixed combination rather than selling cagrilintide alone.

The "resensitizing bridge" - the part that's folklore

Here's where the internet gets ahead of the evidence. A popular biohacker protocol pulls someone off their GLP-1 for a 4–8 week "reset," switching to cagrilintide in the gap, on the theory that GLP-1 receptors "downregulate" and need to "resensitize."

The problem: **the trials studied cagrilintide and semaglutide taken together (a stack), not cagrilintide as a substitute during a holiday (a bridge).** And the underlying premise - that weight-loss plateaus are caused by GLP-1 receptors wearing out and needing a reset - is largely a myth we unpack separately: plateaus are mostly metabolic adaptation, not receptor burnout. The trials tested one specific, fixed combination product under study conditions; they are evidence about CagriSema, not a general case for combining medicines yourself. Using cagrilintide to "resensitize receptors" during a deliberate drug holiday is a theory the data don't test, and stopping a GLP-1 mostly just invites weight regain.

So: the fixed CagriSema combination has trial evidence behind it. Cagrilintide as a receptor-reset bridge is an untested extrapolation.

The honest limits

• It's investigational. Cagrilintide is not approved as a standalone drug anywhere. The CagriSema combination remains under FDA review as of 26 October 2026 following the 18 December 2025 filing, and no FDA advisory committee meeting has been announced. Company guidance points to a decision by late 2026, carried by Novo Nordisk as a Q4 2026 regulatory milestone; there is still no publicly confirmed PDUFA date, and the specific "October 2026" date circulating in trade coverage is an unofficial estimate rather than a published one. The practical point for readers is that the company expects this to resolve by 31 December 2026, so anything written about CagriSema's status should be re-checked rather than relied on. It is not something to source from a website.
• The combo's edge is real but modest versus the best existing dual agonist, and it missed its own efficacy target - and, in REDEFINE 4, its non-inferiority endpoint against tirzepatide.
• GI effects still occur - the combination reduces but doesn't abolish nausea, and tolerability is individual.
• Long-term and withdrawal data are limited - like the rest of the class, stopping likely means regain.

The bottom line, and where this fits

Cagrilintide is a different lever: an amylin pathway that complements, rather than copies, the GLP-1 drugs. It is not a "reset button" for your receptors, and the idea that it is has never been tested. What the REDEFINE trials do show is that the fixed CagriSema combination beat either medicine alone, and the FDA is now weighing that evidence. If you are thinking about where this fits for you, the strongest first step is to know your own starting numbers and talk it through with your own doctor.

Where Vivre Labs fits

Vivre Labs lists cagrilintide, which is investigational and not approved anywhere, alongside semaglutide and tirzepatide, which are approved prescription medicines for weight management. We recommend starting with baseline bloodwork.

Frequently asked questions

Is cagrilintide the same as Ozempic or Mounjaro? No. Ozempic/Wegovy (semaglutide) and Mounjaro (tirzepatide) are incretin drugs (GLP-1, or GLP-1 + GIP). Cagrilintide is an amylin analogue that works through a separate brainstem satiety pathway - which is why it's combined with them rather than compared head-to-head.

How much weight did CagriSema produce in trials? In REDEFINE 1, about −20.4% at 68 weeks (−22.7% with full adherence), versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone. In the separate head-to-head REDEFINE 4 trial it reached 23.0% versus 25.5% for Zepbound (tirzepatide) at 84 weeks.

Is cagrilintide approved? Not as a standalone. It's investigational; the CagriSema combination remains under FDA review as of 26 October 2026, with no publicly confirmed PDUFA date - which is the accurate answer to "when," rather than any specific date. Company guidance points to a decision by late 2026, carried as a Q4 2026 milestone; the "October 2026" date circulating in trade coverage is an unofficial estimate. It is not something to buy online; talk to your own doctor about approved options. More detail: CagriSema: where the FDA review stands.

Does taking cagrilintide "resensitize" my GLP-1 receptors? That's an unproven biohacker theory. The trials tested cagrilintide with semaglutide as a stack, not as a receptor-reset bridge, and plateaus are mostly metabolic adaptation rather than receptor burnout.

Related reading

• CagriSema: where the FDA review stands - the combination's regulatory status, in dates
• Tirzepatide vs semaglutide vs retatrutide vs CagriSema - all four, side by side
• GLP-1 plateau & "resensitizing": myth vs reality - what a stall actually is
• Why your weight loss stalls on a GLP-1 - the consumer-friendly version
• Keeping the weight off after you stop - why stopping invites regain
• Cagrilintide as a bridge or stack, in plain English - the amylin pathway explained from scratch, and whether cagrilintide lowers ghrelin
• When will CagriSema be approved? - where the FDA decision stands

---

Educational content, not medical advice. Cagrilintide and CagriSema are investigational and not approved as standalone treatments; descriptions here are research context. Any metabolic treatment is physician-prescribed and biomarker-monitored. Trial figures describe study populations; individual results vary. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 26 October 2026. Last reviewed: October 2026.

Primary references

• Davies M, Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081. (CagriSema −20.4%; −22.7% full adherence; NCT05567796)
• REDEFINE 2 (cagrilintide–semaglutide in type 2 diabetes). N Engl J Med. 2025. (−13.7% vs −3.1% placebo)
• REDEFINE 4 (CagriSema vs Zepbound/tirzepatide, 84 weeks), reported February 2026: 23.0% vs 25.5%; missed the primary endpoint of non-inferiority on weight loss and established no superiority over the comparator; post-dates and was not the basis of the December 2025 NDA. (Clinical Trials Arena; Drug Topics; HCPLive.)
• Novo Nordisk NDA submitted to the FDA 18 December 2025, based primarily on REDEFINE 1 and REDEFINE 2. No PDUFA date publicly confirmed as of 26 October 2026 - the absence of a confirmed date is the position of record; company guidance points to a decision by late 2026, carried as a Q4 2026 regulatory milestone in Novo Nordisk's Form 6-K FY2026. (PharmExec.)
• Ad-hoc News, Novo Nordisk's Pipeline Has Three Clocks Ticking, 23 October 2026: Q4 2026 decision expected; CagriSema remains investigational.
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. (tirzepatide comparison context)